Interventional Cardiology Global Market

Forecast to 2023

Interventional Cardiology Global Market estimated to be worth $46.1 billion by

2023

IQ4I Research & Consultancy published a new report on Interventional Cardiology

Global Market Forecast To 2023 This report analyzes and studies the overall market,
major drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific
and Rest of the World

IQ4Is Report Contains 163 market data tables and 84 figures spread through 511
pages and an exhaustive TOC on [Interventional Cardiology Product {Catheters
(Guide Catheters, Balloon Catheters, Atherectomy Catheters, Thrombectomy
Catheters, Ablation Catheters), Interventional Diagnostic Catheters (IVUS, FFR, OCT,
Angiographic catheter, Pulmonary artery catheter, Electrophysiology catheter), Stents
(Bare metal stents, Drug eluting stents, Bioresorbable stents, Stent grafts), Valves
(TAVR, Annuloplasty Ring, Mitral Clip, Valvuloplasty), Transcatheter Heart Pump,
Others (Occluders, Inferior Vena cava filter, Guide wires and Accessories)},
Interventional Cardiology Application (Diagnostic Catheterization, Coronary
Interventions, Peripheral Interventions, Structural Heart), REGION (North America,
Europe, Asia-Pacific and Rest of the World)]

This report analyzes the Interventional Cardiology global market in terms of market revenue
($ million) for all segments and it enables Interventional cardiology stakeholders such as
interventional cardiology Products manufacturers, interventional products distributors and
wholesalers, Original equipment manufacturers/Contract manufacturers, Interventional
cardiology associations, Hospitals, Surgeons and group purchasing organizations (GPOs) to
identify and analyze market expansion opportunities, technological advancements and
competition in interventional cardiology global market.

Interventional cardiology deals with the catheter based techniques for the treatment of
cardiovascular diseases such as coronary and peripheral artery diseases, valvular and
congenital heart diseases and structural heart diseases. Interventional cardiology market is
growing at a steady rate, as estimated by IQ4I Research the interventional cardiology global
is expected to grow at high single digit CAGR to reach $46,124.1 million by 2023. Increase
in prevalence of cardiovascular disorders due to rise in aging population, increasing number
of interventional procedures, rise in the number of clinical studies performed, increasing
prevalence of lifestyle diseases are some of the drivers of the market. Technology
advancements and growing healthcare budgetary allocation, growth in emerging countries,
and increase in patient awareness for minimal invasive surgeries are some of the
opportunities that are propelling the growth of the market. However, lack of skilled and

IQ4I Research & Consultancy Pvt. Ltd. Page 1

Interventional Cardiology Global Market

Forecast to 2023

trained professionals and reimbursement issues in emerging countries are some of the
restraints of the market. Stringent regulatory requirements with high cost of development and
availability of alternate products are some of the threats of the market.

The Interventional cardiology global market by products is segmented into catheters, stents,
valves, interventional diagnostic devices, transcatheter heart pump and others.
Interventional cardiology market by applications includes diagnostic catheterization, coronary
interventions, peripheral interventions and structural heart.

Among the products stents held the highest share due to wide acceptance of stent
procedures, a minimal invasive surgery with less risk of complications than open surgery.
Transcatheter heart pump segment is project to grow at a very high double digit CAGR.
Abiomed, U.S. based medical device company has developed worlds smallest catheter
based heart pump that provides hemodynamic support to the heart. The Impella heart pump
(Impella series - Impella 2.5, Impella 5.0, Impella CP, and Impella RP) is FDA approved and
presently is one of the factors for driving Interventional cardiology market.

Among various Interventional cardiology applications, coronary interventions held the

highest share and is expected to grow at a high single digit CAGR due to large acceptance
of non surgical treatments such as PTCA, cardiac ablation, coronary thrombectomy and
aortic aneurysm (EVAR and TEVAR). Structural heart segment is the fastest growing market
with a double digit CAGR. Major companies are adopting acquisition strategy in the
expansion of cardiovascular and structural heart devices product portfolio, for instance, in
January 2017, Abbott Laboratories acquired St. Jude medical. This acquisition has
enhanced Abbotts product offering in emerging high growth areas of cardiovascular device
market such as atrial fibrillation, heart failure and structural heart that elevates the company
to the top position in cardiovascular market. Similarly, Medtronic, PLC in October 2015
acquired Twelve, Inc, a privately-held medical device company focused on the development
of a transcatheter mitral valve replacement (TMVR) device. This acquisition supported
Medtronic to develop a differentiated TMVR product that had significant growth
opportunities.

Transcatheter Mitral Valve Replacement (TMVR), cardiac remodelling, catheter based heart
pump are some of the technological advancements that are going to drive the interventional
cardiology market in coming years. TMVR is still in its clinical trial stage and major
companies are involved in the design and development of TMVR, for instance Edward
Lifesciences is conducting phase-1 clinical trial in evaluating the safety and function of

IQ4I Research & Consultancy Pvt. Ltd. Page 2

Interventional Cardiology Global Market

Forecast to 2023

CardiAQ TMVR device. Similarly, cardiac remodelling devices (remodelling of heart caused
due to heart failure) such as Parachute implant by Cardiokinetix, Inc. and Revivent TC
TransCatheter Ventricular Enhancement System by BioVentrix, Inc. are in the process of
getting regulatory approval. Procyrions aortix is a catheter based small and continuous heart
pump for heart failure patients, designed to help assist the heart muscle and boost localized
blood flow, instead of operating in heart, it is perched in the aorta. Procyrions aortix device
is not yet commercially available and requires regulatory approval from FDA. The launch of
these technologies will boost the interventional cardiology market in coming years.

The Interventional cardiology global market based on geography is divided into North
America, Europe, Asia-Pacific and Rest of the world. North American region commanded the
largest revenue and to grow at high single digit CAGR. Increasing peripheral interventional
procedures, growth in aging population and significant increase in PCI centers in U.S. has
led the market growth in this region. However, Asia-Pacific is expected to grow at highest
CAGR owing to the rapidly increasing aging population, patient and raise in healthcare
awareness in the emerging countries, such as India and China.

Companies such as Boston Scientific, Medtronic, Abbott and Terumo are ahead of other
companies are considered to be leaders in this space with their marketed products and
strong pipelines. Abbott is a leader in coronary and endovascular devices and the first
company to obtain FDA approved bioresorbable stent. Recently company has obtained U.S.
FDA approval for Micra Transcatheter Pacing System (TPS), a smallest cardiac pacemaker
and the most advanced technological device for the treatment of bradycardia (slow or
irregular heart rhythms). In January 2017, W.L.Gore & Associates, Inc. received FDA
approval for Viabahn VBX balloon expandable endoprosthesis for treatment of de novo or
restenotic lesions found in iliac arteries, including lesions at the aortic bifurcation. It is the
first and only balloon expandable stent graft to be approved.

Pediatric interventional cardiology market is advancing at a steady rate, as estimated by IQ4I

Research, the market is expected to grow owing to increasing occurrence of congenital heart
conditions among pediatric patients and other key factors contributing to the growth of the
pediatric interventional cardiology market include advancements in minimally invasive
technologies, increasing awareness of technological advancements, preference for
minimally invasive surgeries and growing R&D investments for novel pediatric interventional
cardiology products. However, stringent and complex regulatory procedures and high cost of
pediatric interventional cardiology procedures are restraining the market.

IQ4I Research & Consultancy Pvt. Ltd. Page 3

Interventional Cardiology Global Market

Forecast to 2023

Major players in the interventional cardiology global market are Abiomed (U.S.), Abbott
Laboratories (U.S.), Boston Scientific (U.S.), B. Braun (Germany), C.R. Bard (U.S.), Cook
Medical (U.S), Edwards Lifesciences (U.S.), Johnson &Johnson (U.S.), Medtronic PLC.
(Ireland), Terumo Corporation (Japan) and W.L.Gore & Associates, Inc. (U.S.).

BioVentrix, (U.S.), Biotronik GMBH & Co. (Germany), Cardiovascular Systems, Inc. (U.S.),
Cardiva Medical, Inc.(U.S.), Cardiokinetix (U.S.), Procyrion (U.S.), Cardinal Health (U.S.),
Getinge Group (Sweden), Goodman Co., Ltd. (Japan), InspireMed Ltd.(Israel), Lepu Medical
(China), Lombard Medical Technologies (U.K.), Meril Life Sciences Pvt. Ltd.(India) and
MicroPort Scientific Corporation (China) are some of the emerging players in the
interventional cardiology market.

Reasons for buying this report:

Analysis of the Interventional cardiology global market by identifying segments by

type, application and geography.
Revenue forecast of the interventional cardiology market and strategic analysis of
each submarket with respect to segmental growth trends.
Analysis of the major market trends and factors driving or inhibiting the growth of the
interventional cardiology global market.
Revenue forecast of the interventional cardiology market with respect to North
America (U.S. and Others), Europe (Germany, France, U.K. and Others), Asia-
Pacific (Japan, China, India and Others) and Rest of the World (RoW) (Brazil,
Middle-East and Others) regions.
Analysis of the opportunities for stakeholders by identifying the high-growth
segments of the market.
Identification of key technology developments and innovations driving the market.
Market share analysis of Interventional cardiology global market by major players,
details of their product offerings, revenues, business strategies and SWOTs
Established and Emerging players and their product offerings.
Revenue forecast of pedatric interventional cardiology market.

IQ4I Research & Consultancy Pvt. Ltd. Page 4

Interventional Cardiology Global Market

Forecast to 2023

FIGURE 1

INTERVENTIONAL CARDIOLOGY GLOBAL MARKET: TECHNOLOGY

SEGMENTATION

Interventional Cardiology Global Market

By Product Type
By Region

Diagnostic Other Transcatheter

Catheters Stents Valves NA
Catheters Interventions Heart Pump

Guide Bare Metal U.S.

IVUS TAVR Occluders
Catheter Stents Others
By
Balloon Drug Annulo Application
FFR IVC Filters
Catheters Eluting plasty Ring EU
Diagnostic
Atherectom Bioresorba
OCT Mitral Clip Others catheterization Germany, France,
y Catheters ble Stents
U.K., Others
Thrombecto Valvulo Coronary
Angiograph Stent Grafts Interventions
my Cath. plasty
APAC
Ablation Peripheral
PAC
Catheters Interventions Japan, China,
EP India, Others
Catheters Structural
Heart
RoW

Brazil, Middle
East, Others

Source: Society for Cardiovascular Angiography and Interventions (SCAI), American Heart Association (AHA),
European society for vascular surgery (ESVS), Cardiovascular Research Foundation (CRF), European Society of
Cardiology (ESC), European Association of Percutaneous Cardiovascular Interventions (EAPIC), Japanese
society for vascular surgery, The Heart Valve Society (HVS), WHO, Industrial Experts and IQ4I Analysis.

IQ4I Research & Consultancy Pvt. Ltd. Page 5